Aurobindo Pharma Ltd said on Thursday it would make and sell U.S.-based COVAXX s COVID-19 vaccine candidate for supply in India and to the United Nations Children s Fund (UNICEF) under a licensing deal.
Health News Roundup: Dogs detect COVID-19 at Santiago airport; Serbia begins vaccination drive and more
In the health sector today, the first 10,000 doses of a 10-million order of the Pfizer-BioNtech COVID-19 vaccine reached Chile while Serbia also began the COVID-19 vaccination drive. Watch the video below for the top health stories of December 24 from all across the world.Devdiscourse News Desk | Updated: 24-12-2020 18:26 IST | Created: 24-12-2020 18:26 IST To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
×
Embed This Media
First Pfizer vaccines arrive in Chile, medics to be inoculated first
Published: Dec 24, 2020
HYDERABAD, India, Dec. 24, 2020 /PRNewswire/
COVAXX s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution
Agreement leverages Aurobindo s existing development, commercial and manufacturing infrastructure
Phase 2/3 clinical trials by COVAXX to begin early 1Q 2021 in Asia, Latin America and USA
Important step in ensuring equitable access and global supply during worldwide pandemic
Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Reuters: ARBN.NS) (Bloomberg: ARBP:IN) and COVAXX, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children s Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.
Hauppauge, New York (Newsfile Corp. - December 24, 2020) - COVAXX, a U.S. company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo
Coronavirus vaccine: India could approve emergency use of vaccines made by Pfizer and Bharat Biotech.
Aurobindo Pharma Ltd on Thursday said it would make and sell US-based COVAXX s Covid-19 vaccine candidate for supply in India and to the United Nations Children s Fund (UNICEF) under a licensing deal.
The Indian pharmaceutical company also has non-exclusive rights to sell the shot, which is currently undergoing an early-stage trial, in certain other emerging markets, the Hyderabad-based company said in an exchange filing.
COVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the US.